期刊文献+

红色诺卡氏菌细胞壁骨架治疗糜烂型口腔扁平苔藓的疗效及安全性 被引量:2

Efficacy and safety of Nocardia rubra cell wall skeleton for the treatment of erosive oral lichen planus
下载PDF
导出
摘要 目的:初步观察红色诺卡氏菌细胞壁骨架(Nocardia rubra cell wall skeleton,Nr-CWS)治疗糜烂型口腔扁平苔藓(erosive oral lichen planus,EOLP)的疗效及安全性。方法:选择60例经临床及组织病理确诊为EOLP的患者,根据随机号随机分入两组,试验组局部使用含Nr-CWS的冻干粉,配合使用生理盐水,对照组局部使用安慰剂(不含Nr-CWS的冻干粉),配合使用生理盐水。分别于初诊以及用药后第1、2、4周复查时记录患者糜烂病损面积大小和疼痛程度的变化,比较治疗前后患者REU量表(reticulation,erythema,ulceration)、视觉模拟量表以及口腔健康影响程度量表(oral health impact profile,OHIP-14)(中文版)评分的差异,并观察初诊和治疗4周后的安全性指标。结果:共纳入EOLP患者62例,其中2例失访,试验组31例,对照组29例,平均年龄分别为(52.9±12.4)岁和(54.07±12.40)岁,两组患者的一般情况及口腔卫生状况差异无统计学意义(P>0.05)。试验组患者在治疗后第1、2、4周口腔扁平苔藓的充血糜烂面积明显缩小(P<0.05),缩小率为81.75%,患者的疼痛指数明显降低(P<0.05),口腔健康影响程度计分明显降低(P<0.05),与对照组相比差异有统计学意义(P<0.05),安全性指标与对照组相比差异无统计学意义。结论:Nr-CWS治疗EOLP具有良好的疗效和安全性。 Objective:To observe the efficacy and safety of Nocardia rubra cell wall skeleton(Nr-CWS)for the treatment of erosive oral lichen planus(EOLP).Methods:Sixty patients with clinically and pathologically diagnosed EOLP were randomly divided into the experimental group and control group according to the random number.Patients in the experimental group were treated with lyophilized powder containing Nr-CWS combined with normal saline.Patients in the control group received topical placebo without Nr-CWS combined with normal saline.Changes in the EOLP lesion area and the patient’s pain level were recorded at the timepoints of weeks 1,2,and 4 after the two different treatments,respectively.The changes of the patient’s REU scoring system(reticulation,erythema,ulceration),the visual analogue scale and the oral health impact score(OHIP-14)were compared between the experimental group and control group after treatment,and the safety indicators of the two groups at the initial diagnosis and after 4 weeks’treatment were also observed,respectively.Results:Totally,62 patients with clinically and pathologically diagnosed EOLP were enrolled,2 of whom were lost to the follow-up,with 31 in the experimental group,and 29 in the control group.The mean age of the experimental group and control group were(52.9±12.4)years and(54.07±12.40)years,respectively.There was no significant difference in the oral periodontal index between the experimental group and control group.In the experimental group,the erosive area of oral lichen planus was significantly reduced 1,2,and 4 weeks after the Nr-CWS’s treatment(P<0.05),the reduction rate was 81.75%,the patient’s pain index was also decreased(P<0.05),and in addition,the OHIP-14 was reduced(P<0.05).The changes of the REU scoring system,the visual analogue scale and the OHIP-14 were significantly different between the experimental group and control group after treatment.There was no significant difference in the safety index between the two groups.Conclusion:The priliminary data show that the Nr-CWS is effective and safe to treat EOLP.
作者 朱正达 高岩 何汶秀 方鑫 刘洋 魏攀 闫志敏 华红 ZHU Zheng-da;GAO Yan;HE Wen-xiu;FANG Xin;LIU Yang;WEI Pan;YAN Zhi-min;HUA Hong(Department of Oral Medicine,eking University School and Hospital of Stomatology&National Clinical Research Center for Oral Diseases&National Engineering Laboratory for Digital and Material Technology of Stomatology&Beijing Key Laboratory of Digital Stomatology,Beijing 100081,China;Department of Oral Pathology,Peking University School and Hospital of Stomatology&National Clinical Research Center for Oral Diseases&National Engineering Laboratory for Digital and Material Technology of Stomatology&Beijing Key Laboratory of Digital Stomatology,Beijing 100081,China)
出处 《北京大学学报(医学版)》 CAS CSCD 北大核心 2021年第5期964-969,共6页 Journal of Peking University:Health Sciences
基金 国家自然科学基金(81730030)。
关键词 红色诺卡氏菌 细胞壁支架 口腔扁平苔藓 治疗结果 安全 Nocardia rubra Cell wall skeleton Oral lichen planus Treatment outcome Safety
  • 相关文献

参考文献4

二级参考文献37

  • 1Arden GB, Kolb H. Antimalarial therapy and early retinal changes in patients with rheumatoid arthritis[ J]. Br Med J, 1966,1 (5482) :270-273.
  • 2Shearer RV, Dubois EL. Ocular changes induced by longterm hydroxychloroquine (plaquenil) therapy [ J ]. Am J Ophthalmol, 1967, 64 ( 2 ) : 245-252.
  • 3Rynes RI, Krohel G, Falbo A, et al. Ophthalmologie safety of long-term hydroxychloroquine treatment[ J]. Arthritis Rheum, 1979, 22(8):832-836.
  • 4Frenkel M. Safety of hydroxychloroquine[J]. Arch Ophthalmol, 1982, 100(5) :841.
  • 5Adams EM, Yocum DE. Bell CL. Hydroxychloroquine in the treatment of rheumatoid arthritis [ J]. Am J Med, 1983, 75(2) :321-326.
  • 6Mackenzle AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials [J]. Am J Med, 1983, 75 ( 1A ) :40-45.
  • 7Rynes RI. Ophthalmologic safety of long-term hydroxychloroquine sultate treatment[J].Am J Med, 1983, 75 (1A) :35-39.
  • 8Runge LA. Risk/benefit analysis of hydroxychloroquine sulfate treahnent in rheumatoid arthritis[J]. Am J Med, 1983, 75(1A) :52-56.
  • 9Bell CL. Hydroxychloroquine sulfate in rheumatoid arthritis: long-term response rate and predictive parameters [J]. Am J Med, 1983, 75(1A):46-51.
  • 10Finbloom DS, Silver K, Newsome DA, et al. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity[J]. J Rheumatol, 1985, 12 ( 4 ) : 692-694.

共引文献414

同被引文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部